Expand CMPX Menu
CMPX MENU

CMPX Stock Posts


Unusual Option Volume

CMPX Compass Therapeutics1.92+0.15 (+8.5%)

Compass Therapeutics trades 2,037 contracts. News: INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
View Details...
Unusual Option Volume

CMPX Compass Therapeutics1.68-0.16 (-8.7%)

Compass Therapeutics trades 2,873 contracts.
View Details...
Unusual Option Volume

CMPX Compass Therapeutics1.88-3.15 (-62.6%)

Compass Therapeutics trades 2,461 contracts. The company has the following event: Webcast to Review Topline Secondary Endpoints from Phase 2/3 COMPANION-002 Study on Apr 27, 2026. News: Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
View Details...
CMPX #CompassTherapeutics stock declines -12.9% in premarket,

Premarket Decliner

CMPX Compass Therapeutics5.03-0.18-3.5%

Premarket:4.38-0.65 (-12.9%)

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

Globe NewswireFri, 24-Apr 4:00 PM
CMPX #CompassTherapeutics stock increases 12.1% after hours.

After Hours Gainer

CMPX Compass Therapeutics5.03-0.18-3.5%

After Hours:5.64+0.61 (+12.1%)

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

Globe NewswireFri, 24-Apr 4:00 PM
CMPX #CompassTherapeutics stock increases 12.5% after hours.

After Hours Gainer

CMPX Compass Therapeutics5.03-0.18-3.5%

After Hours:5.66+0.63 (+12.6%)

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

Globe NewswireFri, 24-Apr 4:00 PM
Load Earlier Posts
Market Data Delayed 15 Minutes